Symbiotec Pharmalab IPO Review - Well-Informed Investors can Park Funds for Medium to Long Term Rewards

Symbiotec Pharmalab Ltd. (SPL) is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. It has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volume terms in Fiscal 2026, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs (excluding androstenedione and hydroxyprogesterone caproate). (Source: F&S Report)

It is the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in Fiscal 2026, (Source: F&S Report) demonstrating the depth of its portfolio. The company manufactures these products using fermentation and multi-step complex chemical reactions. With over 30 years of industry experience, it has evolved from a lab scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organizations.

The company has leveraged its deep capabilities across organic chemistry, biotechnology, and complex injectables to operate as a contract development and manufacturing organization (“CDMO”) variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which it also manufactures its own products. As of March 31, 2026, SPL had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”), fermentation capacity of 300 kiloliters (“KL”). Further, it has commissioned two additional manufacturing facilities at Ujjain, Madhya Pradesh and Mhow, Madhya Pradesh, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum, enabling it to function as a vertically integrated ‘microbe-to-pharmacy’ and ‘farm-to-pharmacy’ platform with cost-efficient operations.

Its biotechnology facilities are equipped with fermenters of 5 KL, 35 KL and 100 KL, providing it flexibility in the scale of operations. Further, the company is in the process of expanding its biologics capacity by adding a proposed dedicated 14 KL (comprising two reactors of 7 KL each) fermentation capacity for biologics manufacturing in Ujjain, Madhya Pradesh. It has demonstrated agility by rapidly embracing technologies such as biotransformation, precision fermentation, double chamber platforms, continuous flow chemistry and integrating them into its manufacturing processes, whichit believes has enabled the company to bring complex products to the market. It has also consistently invested in scaling capacity and infrastructure, which has allowed it to compete effectively with larger global players and address expanding demand. Finally, its commitment to maintaining compliance requirements across regulated markets distinguishes it, and its global quality standards enable it to service pharmaceutical innovators and generics across highly regulated markets, while benefitting from price advantages of its manufacturing operations in Asia.

SPL has a robust product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones, which are used extensively in critical care setups, as well as across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology and gynecology. In molecules such as Hydrocortisone, Testosterone and Methylprednisolone, it holds a global leadership position, capturing over 50% market share of supply by volume, with market shares of 80.1%, 76.4% and 76.0% respectively, in Fiscal 2026. (Source: F&S Report). As of March 31, 2026, it holds 43 drug master files (“DMFs”) registered with the US FDA and 23 certificates of suitability (“CEPs”) from the European Directorate for the Quality of Medicines and HealthCare (“EDQM”).

Its capabilities span three interlinked platforms: (i) organic chemistry, including flow chemistry, hydrogenation, and photochemistry; (ii) biotechnology, including biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (“GLP-1”) and Insulins; and (iii) forward integration into complex injectables including double-chamber vials, double-chamber bags and double-chamber syringes, collectively enabling it to commercialize and scale hard-to-replicate products and services. Its differentiated chemistry capabilities enable it to manufacture APIs and products with up to 400 synthesis steps validated under cGMP efficiently. Its ability to develop and scale niche, complex API products is reflected in its success in developing conjugated estrogen products, where SPL is one of the few companies globally to have successfully developed a complex API with 82 US FDA mandated components despite the product’s primary composition patents having expired several decades prior. (Source: F&S Report)

SPL’s broad capabilities are enabled by conversion of commodity plant-based derivative inputs (farm/ microbe-to- pharmacy approach) and work with diverse microbial strains such as bacteria, fungi, yeast and algae to convert into high value steroid and hormonal pre-cursors. This supports backward integration and underpins its ‘farm/microbe-to-pharmacy’ approach. This integration allows it to make strategic, cost-effective ‘make versus buy’ decisions for key starting materials (“KSMs”) for over 80% of its products by revenue, thereby reducing external dependence for sourcing intermediates from other geographies. The company is among the few backward-integrated Indian and global manufacturers capable of producing in-house corticosteroid and hormone precursors, as of March 31, 2026. (Source: F&S Report).

As of March 31, 2026, it had three complementary verticals, through which it had variably supplied products to over 200 customers in over 40 countries, including leading generic and specialty pharmaceutical companies in the United States, Europe, and Asia – (i) API products, (ii) CDMO services, and (iii) complex injectables. Its research and development (“R&D”) efforts are central to its ability to build, scale, and sustain complex manufacturing technologies. As of March 31, 2026, its R&D team comprised 156 scientists and engineers, including 117 with master’s degrees and 10 with PhDs, engaged in new product development, process innovation, technology transfer and scale-up.

As of March 31, 2026, it operated three dedicated R&D centres in Indore, Madhya Pradesh, focused on driving innovation across organic chemistry, biotechnology and complex injectables. SPL’s commitment to innovation is demonstrated by its investment of 3.42%, 4.14%, 2.86% of revenue from operations into R&D in Fiscals 2026, 2025 and 2024, respectively. As of March 31, 2026, it had a consolidated workforce of over 2,500 employees, including both permanent and contractual staff, providing scale and flexibility across its operations.